Both of these beaten-down cannabis stocks should have great long-term prospects.
And why it’s a potential problem for biotech investors.
Several trends will shape this decade. And there's one stock that should benefit from all of them.
All three stand to benefit from major long-term growth trends.
Strong dividends. Solid businesses. Retirees should love these three stocks.
It's not just their cancer treatments that make these stocks attractive.
These two big drugmakers are in very different positions right now. And one is the clear choice for long-term investors.
Can these high-flying biotech stocks keep up their sizzling momentum?
The federal agency is concerned that the tobacco giant failed to adequately disclose the risk it was taking with investing in JUUL.
The worst performer among these stocks has soared more than 70% over the last 12 months.
The provider of an online health insurance exchange blew past Wall Street revenue and earnings estimates.
The hospital operator easily beat Wall Street revenue and earnings expectations with its Q4 results.
The hospital operator handily beat expectations with its Q4 results.
Two of these Canadian pot stocks could have especially bright prospects.
Demand continued to be strong for the medical technology company's pulse oximetry devices.
This high-flying stock's momentum could falter after missing Wall Street's revenue expectations.
Investors reacted enthusiastically to a positive coverage decision for the company's Eversense CGM device.
The animal-health company posted lower-than-expected revenue in Q4.
The healthcare company narrowly topped revenue expectations in Q4 but failed to meet Wall Street's earnings estimate.
Some think the beaten-down marijuana stock is a lost cause. Others think it could make a major comeback.